90Y-DOTA-lanreotide

**90Y-DOTA-lanreotide** is a radiolabeled somatostatin analog in which the peptide lanreotide is conjugated to the chelator DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) and subsequently complexed with the radioactive isotope yttrium-90 (90Y). This compound is designed as a **radiopharmaceutical** for targeted therapy of tumors expressing somatostatin receptors, such as neuroendocrine tumors and selected carcinomas. The mechanism of action involves **binding of lanreotide to somatostatin receptors** (primarily somatostatin receptor subtype 2) overexpressed on tumor cells, delivering cytotoxic beta radiation directly to the tumor when internalized, causing cell damage and death. The DOTA chelator provides stable linkage of yttrium-90 to the peptide for safe and efficient in vivo delivery[9].

Other names

90Y-DOTALANYttrium-90-labeled DOTA-lanreotideYttrium90-labeled DOTA-lanreotideYttrium 90-labeled DOTA-lanreotide